Revlimid boosts survival in myeloma patients post-transplant

03:16 EDT 28 Jul 2017 | PharmaTimes

Celgene has unveiled a meta-analysis of pooled data from three late-stage studies showing a significant overall survival benefit in patients newly diagnosed with multiple myeloma receiving Revlimid as maintenance therapy following autologous stem cell transplantation.

Original Article: Revlimid boosts survival in myeloma patients post-transplant


More From BioPortfolio on "Revlimid boosts survival in myeloma patients post-transplant"

Quick Search

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...